methscopolamine

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Dose	Unit	Route
12	mg	O
12	mg	P

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	-1.295		Moderate	0.70
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.436		Moderate	0.70
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	0.488	10^-6 cm/s	Moderate	0.70
dh-clint	Dog hepatocyte intrinsic clearance	2.360	uL/min/10^6 cells	Moderate	0.70
dppb	Dog plasma protein binding (% unbound)	90.740	%	Moderate	0.70
fcs-ppb	Fetal calf serum protein binding (% unbound)	76.810	%	Moderate	0.70
herg	hERG pIC50	4.190	pIC50	Moderate	0.70
hh-clint	Human hepatocyte intrinsic clearance	1.306	uL/min/10^6 cells	Moderate	0.70
hlm-clint	Human liver microsomal intrinsic clearance	3.177	uL/min/mg protein	Moderate	0.70
hppb	Human plasma protein binding (% unbound)	79.850	%	Moderate	0.70
kinase-safety-class	ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK4,PRKDC,TEK,TGFBR1	20
kinase-selectivity-class	CHUK,EIF2AK3,MAP2K6	3
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	0.391		Moderate	0.70
mh-clint	Mouse hepatocyte intrinsic clearance	5.082		Moderate	0.70
mppb	Mouse plasma protein binding (% unbound)	89.530		Moderate	0.70
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	0.641		Moderate	0.70
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	88.350	%	Moderate	0.70
rh-clint	Rat hepatocyte intrinsic clearance	4.808	uL/min/10^6 cells	Moderate	0.70
rh-fuinc	Rat hepatocyte fraction unbound in incubation	96.160	%	Moderate	0.70
rppb	Rat plasma protein binding (% unbound)	81.260	%	Moderate	0.70
solubility-dd	Solubility at pH 7.4 in DMSO	860.994	uM	Moderate	0.70

Source	Code	Description
ATC	A03BB03	ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS BELLADONNA AND DERIVATIVES, PLAIN Belladonna alkaloids, semisynthetic, quaternary ammonium compounds
ATC	A03CB01	ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS Belladonna and derivatives in combination with psycholeptics
ATC	S01FA03	SENSORY ORGANS OPHTHALMOLOGICALS MYDRIATICS AND CYCLOPLEGICS Anticholinergics
FDA MoA	N0000175370	Cholinergic Antagonists
FDA EPC	N0000175574	Anticholinergic
MeSH PA	D010276	Parasympatholytics
CHEBI has role	CHEBI:48876	muscarinic antagonists
CHEBI has role	CHEBI:50370	parasympatholytics
CHEBI has role	CHEBI:50919	antiemetico
CHEBI has role	CHEBI:53784	antispasmodics

Disease	Relation	SNOMED_ID	DOID
Vasomotor rhinitis	indication	8229003	DOID:4730
Irritable bowel syndrome	indication	10743008	DOID:9778
Cough	indication	49727002
Allergic rhinitis	indication	61582004
Nasal discharge	indication	64531003
Nasal congestion	indication	68235000
Common cold	indication	82272006	DOID:10459
Rhinitis	off-label use	70076002	DOID:4483
Seasonal allergic rhinitis	off-label use	367498001
Brain damage	contraindication	2470005
Ocular hypertension	contraindication	4210003	DOID:9282
Tachyarrhythmia	contraindication	6285003
Suicidal thoughts	contraindication	6471006
Urinary tract obstruction	contraindication	7163005	DOID:5200
Peptic ulcer	contraindication	13200003	DOID:750
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Severe chronic ulcerative colitis	contraindication	14311001
Disorder of lung	contraindication	19829001	DOID:850
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Ventricular tachycardia	contraindication	25569003
Alcohol intoxication	contraindication	25702006
Shock	contraindication	27942005
Toxic megacolon	contraindication	28536002	DOID:1770
Atony of colon	contraindication	29479008
Hyperthyroidism	contraindication	34486009	DOID:7998
Depressive disorder	contraindication	35489007
Acute hepatitis	contraindication	37871000
Hypertensive disorder	contraindication	38341003	DOID:10763
Complete trisomy 21 syndrome	contraindication	41040004	DOID:14250
Hyperactive behavior	contraindication	44548000
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Acidosis	contraindication	51387008
Coronary arteriosclerosis	contraindication	53741008	DOID:3393
Paralytic ileus	contraindication	55525008	DOID:8442
Peptic reflux disease	contraindication	57643001
Ulcerative colitis	contraindication	64766004	DOID:8577
Arterial thrombosis	contraindication	65198009
Drug AND/OR toxin-induced diarrhea	contraindication	65979008
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Arteriosclerotic vascular disease	contraindication	72092001
Diabetes mellitus	contraindication	73211009	DOID:9351
Sleep apnea	contraindication	73430006	DOID:0050847
Spastic paralysis	contraindication	78403003
Disturbance of salivary secretion	contraindication	78948009
Chronic idiopathic constipation	contraindication	82934008
Hiatal hernia	contraindication	84089009	DOID:12642
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Hypoalbuminemia	contraindication	119247004
Gastrointestinal obstruction	contraindication	126765001
Autonomic dysreflexia	contraindication	129618003
Bleeding	contraindication	131148009
Partial atrioventricular block	contraindication	195039008
Acute pancreatitis	contraindication	197456007	DOID:2913
Myocardial dysfunction	contraindication	233928007
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Pyloric obstruction	contraindication	244815007
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Drowsy	contraindication	271782001
Pregnancy, function	contraindication	289908002
Severe chronic obstructive pulmonary disease	contraindication	313299006
Hypoxia	contraindication	389086002
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Gastric ulcer	contraindication	397825006	DOID:10808
Breastfeeding (mother)	contraindication	413712001
Chronic lung disease	contraindication	413839001
Disorder of coronary artery	contraindication	414024009
Porphyria	contraindication	418470004
Hypertensive urgency	contraindication	443482000

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	ANTAGONIST	Ki	9.90	IUPHAR	CHEMBL
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Ki	10.40	IUPHAR	IUPHAR
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	9.82	CHEMBL
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	10.01	CHEMBL
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	9.68	CHEMBL
Muscarinic acetylcholine receptor M3	GPCR		ACM3_RAT		EC50	10.30	CHEMBL

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

methscopolamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

ID	Source
4019830	VUID
N0000147918	NUI
155-41-9	SECONDARY_CAS_RN
6106-46-3	SECONDARY_CAS_RN
4018075	VANDF
4018747	VANDF
4019830	VANDF
C0301374	UMLSCUI
3C0	PDB_CHEM_ID
CHEMBL376897	ChEMBL_ID
CHEMBL1354199	ChEMBL_ID
DB11315	DRUGBANK_ID
71183	PUBCHEM_CID
VDR09VTQ8U	UNII
DB00462	DRUGBANK_ID
56092	RXNORM
5082	MMSL
5083	MMSL
92758	MMSL
d00989	MMSL
001720	NDDF
001721	NDDF
001722	NDDF
28415002	SNOMEDCT_US
372690005	SNOMEDCT_US
49371000	SNOMEDCT_US
713368001	SNOMEDCT_US
717775003	SNOMEDCT_US
D019832	MESH_DESCRIPTOR_UI
CHEBI:135361	CHEBI
316	IUPHAR_LIGAND_ID
VDR09VTQ8U	INXIGHT DRUGS

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
METHSCOPOLAMINE BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	43063-740	TABLET	2.50 mg	ORAL	ANDA	22 sections
METHSCOPOLAMINE BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	43063-740	TABLET	2.50 mg	ORAL	ANDA	22 sections
METHSCOPOLAMINE BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	43063-741	TABLET	5 mg	ORAL	ANDA	22 sections
METHSCOPOLAMINE BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	43063-741	TABLET	5 mg	ORAL	ANDA	22 sections
Methscopolamine Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	51991-191	TABLET	2.50 mg	ORAL	ANDA	24 sections
Methscopolamine Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	51991-192	TABLET	5 mg	ORAL	ANDA	24 sections
METHSCOPOLAMINE BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	72162-2471	TABLET	2.50 mg	ORAL	ANDA	14 sections
METHSCOPOLAMINE BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	72162-2472	TABLET	5 mg	ORAL	ANDA	14 sections
METHSCOPOLAMINE BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	72319-029	TABLET	2.50 mg	ORAL	ANDA	22 sections
METHSCOPOLAMINE BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	72319-030	TABLET	5 mg	ORAL	ANDA	22 sections
METHSCOPOLAMINE BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	76385-100	TABLET	2.50 mg	ORAL	ANDA	14 sections
METHSCOPOLAMINE BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	76385-101	TABLET	5 mg	ORAL	ANDA	14 sections